Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer.

PLoS One · 2021 · PMC8248740 · PMID 34197475

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Further subgroup analysis unveiled a decreasing trend of median of log( MSD (RECIST) ) with the highest in the mix of progression and regression (n = 7; 19%), followed by the mix of progression and stability (n = 9; 25%), then by the mix of regression and stability (n = 5; 14%), and lastly by the non-heterogeneity (n = 15; 42%).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.